PTO/SB/08x (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COM-U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COM-Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control.

	F
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	F
(Not for submission under 37 CFR 1.99)	A
,	E

Application Number					
Filing Date		2006-05-30			
First Named Inventor Take		shi Horie			
Art Unit Examiner Name					
Attornou Docket Numb	or.	00702000 6708			

					U.S.I	PATENTS			Remove		
Examiner Initial*	Examiner Cite No Patent Number Kind Code1		Date	Name of Patentee or Applicant Re		Releva	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1										
If you wis	h to a	i dd additional U.S. Patei	nt citatio	n inform	ation pl	l lease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relev	
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	,		n information p		d button	Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	y	Kind Code4	Publication	Name of Patente Applicant of cited Document	e or	vhere Rele	or Relevant	+-
	1	2003-192925	JP			2003-07-09	Sony Corp				
	2	2002-302568	JP			2002-10-18	Ishizuka Garasu Kabushiki Kaisha				Г
	3	2002-338816	JP			2002-11-27	Ishizuka Garasu Kabushiki Kaisha				

2003-11-19

Kishizuka Garasu

Kahushiki Kaisha

	5	2003-	89721	JP		2003-03-28	Sony Corp			
	6	2003-	165917	JP		2003-06-10	Sony Corp			
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
	NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*	Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publishers							Ţ5		
	1									
If you wish to add additional non-patent literature document citation information please click the Add button Add										
				EX	AMINE	R SIGNATUR	E			
Examiner	Signs	ature					Date Considered			

See Kinz Code of USPTO Patent Documents at twen USPTO_GOUY or MPEP 801.64. Estimation that issued the document, by the two-letter good (WIPO Standard S13.). For jumpness patent counters, the necladard on the year of the register present person the common that the patent document. If the following the patent document is the document by the appropriate symbols as andicated on the document under WIPO Standard S11.6 if possible. Applicant is to place a check mark here if English languages translation as statistics.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

2003-327842

Application Number Filing Date 2006.65.30 Fil

CERTIFICATION STATEMENT

so to make the appropriate selection(s).	

That each item of information contained in the information disclosure statement was first cited in any communication

from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(a/1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign parter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 159(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1379(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_					
Signature	/David R. Metzger/	Date (YYYY-MM-DD)	2006-05-31		
Name/Print	David R. Metzger	Registration Number	32919		

This collection of information is required by 37 CFR 197 and 1.98. The information is required to obtain or retain a benefit by the public which is for like and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 122 and 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. Operatment of Commence, P. 0. Bot 1450, Alexandrio, V.2.923.1-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.2.2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.